ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026.

 

We dived into key studies and recent FDA approvals, including:

• The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer.
• The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs.
• Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies.
• Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments.
• A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them.

Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights.

 

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers 
• ⁠Instagram: https://www.instagram.com/oncbrothers 
• Website: https://oncbrothers.com/ 

 

Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers!

#ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers